Shares of Novavax, Inc. (NVAX) plunged over 19.5% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr.

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, with the long-time vaccine critic declaring that vaccines for respiratory bugs that target a sole part of ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail emerging and cutting-edge vaccines that are now awaiting regulatory approval ...

The former top vaccines official at the Food and Drug Administration criticized Health and Human Services Secretary Robert F.

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

The health secretary has chipped away at the idea that immunizing children against measles and other diseases is a public ...

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.

The Novavax vaccine, which uses more traditional protein-based technology than the newer mRNA vaccines from Pfizer/BioNTech and Moderna, has been subject to emergency use authorization since 2022.